Navigation Links
NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
Date:4/1/2009

in December 2008. This patent will expire in 2026. NovaBay has recently filed additional patent applications that cover compositions of matter of additional Aganocide compounds, methods of use and formulations, and is preparing further applications in other areas.

Financial Results

Fourth Quarter 2008 Financial Results

License and collaboration revenue for the fourth quarter of 2008 increased 44% to $2.2 million from $1.5 million for the fourth quarter of 2007. License and collaboration revenue consists of the amortization of the upfront technology access fees previously paid, and reimbursements for the funding of research and development activities.

The net loss for the fourth quarter of 2008 was $(1.5) million, or $(0.07) per share, compared to a net loss of $(1.4) million, or $(0.09) per share, reported for the fourth quarter of 2007.

Research and development expenses for the quarter ended December 31, 2008 totaled $3.3 million, compared to $1.8 million for the quarter ended December 31, 2007. The increase was largely due to the timing of pre-clinical and clinical trials.

General and administrative expenses for the quarter ended December 31, 2008 were $0.5 million, compared to $1.2 million in the comparable 2007 period.

NovaBay ended the quarter and year with $12.1 million in cash and cash equivalents.

Full Year 2008 Financial Results

For the full year 2008, license and collaboration revenue totaled $6.7 million, compared to $5.9 for the year 2007.

NovaBay reported a net loss of $(8.1) million, or $(0.38) per share, for the full year 2008, compared to a net loss of $(5.4) million, or $(0.60) per share, for the full year 2007.

Research and development expenses for the full year 2008 were $9.6 million compared with
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBays Novel Aganocide Drugs for Major Dermatological Conditions
2. NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock
3. Alseres Pharmaceuticals, Inc. Complies with NASDAQ Rule Regarding Recently Filed 10-K
4. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
5. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
6. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
7. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
9. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
10. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
11. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014 According to ... "Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, ... - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - ... 2013 - 2019," the global electrodes market for medical ... and is estimated to reach a market worth USD ...
(Date:7/31/2014)... Senomyx , Inc. (NASDAQ: ... taste science technologies to discover, develop, and commercialize ... ingredient supply industries, today reported financial results for ... second quarter with $33.6 million in cash and ... past quarter Senomyx achieved another important milestone with ...
(Date:7/31/2014)... Calif. (PRWEB) July 31, 2014 Held ... diagnosed patients with an overview of the disease and ... of drug side effects, as well as updates on ... grateful to Dr. Sandy Srinivas for organizing this educational ... of kidney cancer. “Sandy and her colleagues have put ...
(Date:7/31/2014)... Canada (PRWEB) July 31, 2014 ... some of the first transcriptome-wide analyses appearing around ... standard assay for RNA measurement. In the last ... throughput, more specific, work with smaller input amounts, ... tissues (eg, blood samples). On the bioinformatics side, ...
Breaking Biology Technology:Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 2Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 4Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 5Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16The Evolution of RNA-Sequencing, Upcoming Live Webinar August 22 hosted by Xtalks 2
... Inc. (OTC Bulletin Board: WGBS), a leading ... and stem cell,research systems, today announced the ... company,s SmartSlide(TM) Micro-Incubation System with,Labtech International Limited ... in,France. The distributor agreement covers WaferGen,s entire ...
... 25 Senesco,Technologies, Inc. (the "Company") (Amex: ... the American Stock Exchange ("AMEX") stating that the ... the AMEX,s,letters dated June 15, 2007 and October ... of publicly available information pertaining to the Company,including ...
... March 25 Epeius Biotechnologies,Corporation announced today ... for,Targeted Gene Delivery in vivo. This patent ... of highly advanced,biotechnologies embodied in the company,s ... intravenous infusion, the Epeius,tumor-targeted gene delivery system ...
Cached Biology Technology:WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in United Kingdom and France 2WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in United Kingdom and France 3WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in United Kingdom and France 4WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in United Kingdom and France 5Senesco Technologies Regains Compliance With Amex's Continued Listing Requirements 2Senesco Technologies Regains Compliance With Amex's Continued Listing Requirements 3Epeius Biotechnologies Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo 2
(Date:7/31/2014)... Fire was in full fury, raging swiftly from crown ... backcountry of Yosemite National Park in California,s Sierra Nevada ... battle began to turn, enacting a case study in ... fuel large, severe fires. , "When the Rim Fire ... had been used as a management tool, rather than ...
(Date:7/31/2014)... familiar with Hibiscus flowers- they are an iconic ... commonly planted in the landscape. Some, like Hawaii,s ... species. , Only a relatively few botanists and ... equally beautiful and intriguing related group of plants ... Hibiscus". , Brother of Hibiscus species are in ...
(Date:7/31/2014)... White, brown and beige adipocytes, or fat cells, are ... functions and each plays its own role in metabolism. ... far the most prevalent. Its primary function is energy ... energy to generate heat but are only found in ... adipocytes, which represent a special type of brown adipocytes, ...
Breaking Biology News(10 mins):The Rim Fire 1 year later: A natural experiment in fire ecology and management 2The Rim Fire 1 year later: A natural experiment in fire ecology and management 3The Rim Fire 1 year later: A natural experiment in fire ecology and management 4The Rim Fire 1 year later: A natural experiment in fire ecology and management 5Brother of Hibiscus is found alive and well on Maui 2Hope for the overweight 2
... Conservation Society's New York Aquarium received the ultimate honor ... island nation of Madagascar was named after him. , ... career safeguarding Madagascar's little- known freshwater fishes, received the ... Museum of Natural History (AMNH), after they named a ...
... Researchers at Johns Hopkins have discovered to their surprise ... can also block angiogenesis, the growth of new blood ... is FDA approved for human use, which may fast-track ... mice induced to have excess blood vessel growth, treatment ...
... corn grain is diverted to make ethanol, there have ... from cellulosic materials instead of corn grain, renders the ... a Michigan State University ethanol expert. , Bruce Dale, ... used life cycle analysis tools, which include agricultural data ...
Cached Biology News:Anti-fungal drug stops blood vessel growth 2With cellulosic ethanol, there is no food vs. fuel debate according to MSU scientist 2
... for the use of small interfering RNA ... the RNA interference (RNAi) pathway have generated ... biology fields. siRNA for experimental use can ... enzymatically, and then transfected into the target ...
... potential applications for the use of small ... expression via the RNA interference,(RNAi) pathway have ... molecular biology fields. siRNA for experimental use ... enzymatically, and then transfected into the target ...
... The HybArray 12™ is an automated hybridization ... The system automates both the hybridization and ... glass slides. A single instrument can process ... in pairs and has multi-protocol software, enabling ...
... is commonly used as a fusion partner ... The GSTTag sequence has been reported to ... the solubility of its fusion partners. When ... GSTTag fusion proteins can be purified with ...
Biology Products: